Lapatinib shows minimal effect against liver cancer
Wednesday, September 9, 2009 - 09:07
in Health & Medicine
Use of the molecularly targeted agent lapatinib to delay tumour growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumour response and longer survival...